Aurobindo Pharma Ltd. has secured final approval from the U.S. Food and Drug Administration (FDA) to manufacture and market Cephalexin Tablets USP, an antibiotic used to treat a range of bacterial infections. The approval covers 250 mg and 500 mg dosages of the drug.
The approved Cephalexin tablets are bioequivalent and therapeutically equivalent to the reference listed drug, Keflet tablets, in the same dosages. This equivalence ensures that the generic version provides the same clinical benefit and safety profile as the original brand-name drug. Cephalexin is a cephalosporin antibiotic used to treat infections caused by susceptible strains of specific microorganisms. These infections can include respiratory tract infections, skin and soft tissue infections, and urinary tract infections.
Competitive Generic Therapy Designation
Aurobindo Pharma has also been granted Competitive Generic Therapy (CGT) designation for these Cephalexin tablets. This designation may qualify the company for 180 days of shared generic drug exclusivity, providing a competitive advantage in the market. The CGT pathway is designed to encourage the development and market entry of generic drugs for which there is limited competition.
Market Launch and Availability
The company anticipates launching the Cephalexin tablets in the third quarter of the financial year 2025. This launch will expand Aurobindo Pharma's portfolio of generic pharmaceuticals and provide a cost-effective alternative for patients requiring cephalexin treatment.
Aurobindo Pharma, headquartered in Hyderabad, India, is a global pharmaceutical company focused on developing, manufacturing, and commercializing a wide range of generic pharmaceuticals. The company's products are available in more than 125 countries.
